Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
D3 Bio (Wuxi) Co. Ltd. is currently overseeing 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. This volume of activity suggests a focused prosecution phase for the company's pharmaceutical developments, where each filing is handled as a distinct technical inquiry.
The 3 pending office actions are distributed across a matching number of distinct examiners and 3 distinct art units. This distribution means that each active matter is being handled by a different specialist in a separate section of the patent office, requiring the company to navigate three different administrative paths simultaneously.
SHTERENGARTS, SAMANTHA L is the busiest examiner, currently managing 1 pending office action. Since each of the distinct examiners is responsible for exactly one matter, the company must address different sets of examiner expectations to successfully resolve its 3 pending office actions. Legal strategy should focus on maintaining technical consistency across these 3 distinct art units while addressing individual examiner concerns.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (33%) |
| Double-patenting + other | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SHTERENGARTS, SAMANTHA L | 1 | 79.5% | +8.0% |
| HAVLIN, ROBERT H | 1 | 51.3% | +28.3% |
| WELLS, LAUREN QUINLAN | 1 | 49.4% | +59.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18923767 | PYRIMIDOHETEROCYCLIC COMPOUNDS AND APPLICATION THEREOF | SHTERENGARTS, SAMANTHA L | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18571076 | THIAZOLE-LACTAM-SPIROHETEROCYCLIC COMPOUNDS AND APPLICATIONS THEREOF | HAVLIN, ROBERT H | 11d overdue |
| 18571087 | DIMETHYL-SUBSTITUTED THIAZOLOLACTAM COMPOUND AND USE THEREOF | WELLS, LAUREN QUINLAN | — |
| Art Unit | Apps |
|---|---|
| 1623 | 1 |
| 1626 | 1 |
| 1622 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18923767 | PYRIMIDOHETEROCYCLIC COMPOUNDS AND APPLICATION THEREOF | SHTERENGARTS, SAMANTHA L | 1623 | §101DP | Non-Final OA | — | Pending | Oct 23, 2024 |
| 18571076 | THIAZOLE-LACTAM-SPIROHETEROCYCLIC COMPOUNDS AND APPLICATIONS THEREOF | HAVLIN, ROBERT H | 1626 | §103DP | Final Rejection | 11d overdue | Pending | Dec 15, 2023 |
| 18571087 | DIMETHYL-SUBSTITUTED THIAZOLOLACTAM COMPOUND AND USE THEREOF | WELLS, LAUREN QUINLAN | 1622 | §103DP | Final Rejection | — | Pending | Dec 15, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialD3 Bio (Wuxi) Co. Ltd. has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Samantha L Shterengarts has the most, with 1 of D3 Bio (Wuxi) Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
